Utilization of Oligonucleotides’ Half-Life to Optimize Dosing Regiment for Desirable Efficacy & Reduced CNS Toxicity

• Explore how chemical modifications and structural engineering can make oligos more resistant to nuclease degradation
• Understand the impact of half-life extension on dosing frequency, therapeutic window, and patient compliance
• Learn how conjugation to long-circulating carriers like antibodies can enhance PK/PD profiles and tissue retention

Speakers:

Meena Indrakanti

Senior Vice President, Translational DMPK and Clinical Pharmacology

Stoke Therapeutics